Retatrutide vs Tirzepatide
| Attribute | Retatrutide Triple agonist (GLP-1/GIP/Glucagon) | Tirzepatide Dual GIP/GLP-1 receptor agonist |
|---|---|---|
| Category | Weight Loss & Metabolism | Weight Loss & Metabolism |
| Best known for | Triple-receptor metabolic research | Dual-agonist weight loss research |
| In plain English | Retatrutide pulls three levers — appetite, insulin response, and energy expenditure via glucagon. Trials have shown the largest weight reductions of any incretin to date. | Tirzepatide is like semaglutide with an extra lever pulled. It hits two appetite/insulin pathways at once, producing larger weight reduction in studies. |
| How it works | GLP-1 reduces appetite. GIP enhances insulin response. Glucagon receptor activation increases energy expenditure and fat oxidation. | Co-activates GLP-1 and GIP receptors. GIP enhances insulin response and may help adipose tissue handle nutrients more efficiently while GLP-1 reduces appetite and slows gastric emptying. |
| Researchers study | Obesity, hepatic steatosis, and metabolic syndrome. | Type 2 diabetes glycemic control, obesity, NASH/MASH, and cardiovascular outcomes. |
| Internet discussion | Treated as the 'next big thing' in metabolic forums. Discussion centers on side effect profile vs tirzepatide. | Often described as 'semaglutide on steroids' for weight loss. Heavy discussion of side effect differences and titration schedules. |
Retatrutide
Triple-receptor metabolic research
Retatrutide pulls three levers — appetite, insulin response, and energy expenditure via glucagon. Trials have shown the largest weight reductions of any incretin to date.
GLP-1 reduces appetite. GIP enhances insulin response. Glucagon receptor activation increases energy expenditure and fat oxidation.
Obesity, hepatic steatosis, and metabolic syndrome.
Treated as the 'next big thing' in metabolic forums. Discussion centers on side effect profile vs tirzepatide.
Retatrutide is an investigational triple agonist showing the largest weight-loss signals in metabolic research to date.
Tirzepatide
Dual-agonist weight loss research
Tirzepatide is like semaglutide with an extra lever pulled. It hits two appetite/insulin pathways at once, producing larger weight reduction in studies.
Co-activates GLP-1 and GIP receptors. GIP enhances insulin response and may help adipose tissue handle nutrients more efficiently while GLP-1 reduces appetite and slows gastric emptying.
Type 2 diabetes glycemic control, obesity, NASH/MASH, and cardiovascular outcomes.
Often described as 'semaglutide on steroids' for weight loss. Heavy discussion of side effect differences and titration schedules.
Tirzepatide is a dual GLP-1/GIP agonist with strong clinical data for weight reduction and glycemic control.